Actualités Antibe Therapeutics Inc - ATE | Actions Toronto Stock Exchange

Antibe Announces Appointment of Receiver

Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE) announced that the Company’s request for an extension of its previously announced...

Antibe Provides Update on CCAA Proceedings

Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE) announced that the Company sought an extension of its previously announced stay...

Antibe Announces TSX Delisting Review

Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE) announced that the Toronto Stock Exchange (“TSX”) is reviewing the eligibility...

Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act

Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE, OTCQX: ATBPF) announced that its previously announced application for an Initial...

Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act

Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX: ATE, OTCQX: ATBPF) announced that it intends to file an application today with the...

Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance

Antibe Therapeutics Inc. (“Antibe” or the “Company” TSX: ATE, OTCQX: ATBPF) today announced that it received verbal notice on the afternoon of...

Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting

- The American Society of Regional Anesthesia and Pain Medicine is the largest subspecialty medical society in anesthesiology Antibe Therapeutics...

Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting

- AAPM is the primary organization for pain medicine physicians in the U.S. Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage...

Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target pain...

Antibe Reports Q3 2024 Interim Financial and Operating Results

- Successful PK/PD study confirms liver safety, sets stage for upgraded Phase II trial launch next month - Phase II trial enhancements include...

Antibe Extends Early Warrant Exercise Incentive Program

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation...

Antibe Announces Early Warrant Exercise Incentive Program

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation...

Antibe Therapeutics Announces Amendment to Warrant Terms

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) (the "Company"), a clinical stage company leveraging its hydrogen sulfide platform to develop...

Antibe Reports Q2 2024 Interim Financial and Operating Results

- Completed successful PK/PD study for otenaproxesul’s new formulation - Phase II initiation on track for upcoming quarter - Ended quarter with...

Antibe Reports PK Results of First Clinical Study of Otenaproxesul’s New Formulation

- Study delivers data required for Phase II trial, on track to initiate next quarter - Confirms linear, dose-proportional pharmacokinetics...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Antibe Therapeutics Inc (ATE)

Outils de qualité professionnelle, pour des investisseurs individuels.

ATE Actualités

Antibe Announces Appointment of Receiver

Antibe Provides Update on CCAA Proceedings

Antibe Announces TSX Delisting Review

Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act

Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act

Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance

Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting

Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting

Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma

Antibe Reports Q3 2024 Interim Financial and Operating Results

Antibe Extends Early Warrant Exercise Incentive Program

Antibe Announces Early Warrant Exercise Incentive Program

Antibe Therapeutics Announces Amendment to Warrant Terms

Antibe Reports Q2 2024 Interim Financial and Operating Results

Antibe Reports PK Results of First Clinical Study of Otenaproxesul’s New Formulation

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Antibe Therapeutics Inc (ATE) Actualités

Antibe Therapeutics Inc (ATE)

Outils de qualité professionnelle, pour des investisseurs individuels.

ATE Actualités

Antibe Announces Appointment of Receiver

Antibe Provides Update on CCAA Proceedings

Antibe Announces TSX Delisting Review

Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act

Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act

Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance

Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting

Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting

Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma

Antibe Reports Q3 2024 Interim Financial and Operating Results

Antibe Extends Early Warrant Exercise Incentive Program

Antibe Announces Early Warrant Exercise Incentive Program

Antibe Therapeutics Announces Amendment to Warrant Terms

Antibe Reports Q2 2024 Interim Financial and Operating Results

Antibe Reports PK Results of First Clinical Study of Otenaproxesul’s New Formulation

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application